1,113
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: RADIOTHERAPY

Variation in relative biological effectiveness for cognitive structures in proton therapy of pediatric brain tumors

, ORCID Icon, , , , , , ORCID Icon, , , & ORCID Icon show all
Pages 267-274 | Received 07 Aug 2020, Accepted 15 Oct 2020, Published online: 02 Nov 2020
 

Abstract

Background

Clinically, a constant value of 1.1 is used for the relative biological effectiveness (RBE) of protons, whereas in vitro the RBE has been shown to vary depending on physical dose, tissue type, and linear energy transfer (LET). As the LET increases at the distal end of the proton beam, concerns exist for an elevated RBE in normal tissues. The aim of this study was therefore to investigate the heterogeneity of RBE to brain structures associated with cognition (BSCs) in pediatric suprasellar tumors.

Material and methods

Intensity-modulated proton therapy (IMPT) plans for 10 pediatric craniopharyngioma patients were re-calculated using 11 phenomenological and two plan-based variable RBE models. Based on LET, tissue dependence and number of data points used to fit the models, the three RBE models considered the most relevant for the studied endpoint were selected. Thirty BSCs were investigated in terms of RBE and dose/volume parameters.

Results

For a representative patient, the median (range) dose-weighted mean RBE (RBEd) across all BSCs from the plan-based models was among the lowest (1.09 (1.02–1.52) vs. the phenomenological models at 1.21 (0.78–2.24)). Omitting tissue dependency resulted in RBEd at 1.21 (1.04–2.24). Across all patients, the narrower RBE model selection gave median RBEd values from 1.22 to 1.30.

Conclusion

For all BSCs, there was a systematic model-dependent variation in RBEd, mirroring the uncertainty in biological effects of protons. According to a refined selection of in vitro models, the RBE variation across BSCs was in effect underestimated when using a fixed RBE of 1.1.

Acknowledgments

The project has been funded by The Norwegian Cancer Society (Grant no. 202089).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.